A large-scale real-world study in the USA has reinforced the effectiveness of Beyfortus (nirsevimab-alip), the respiratory ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks Consensus Estimate. Core earnings of $2.17 per share rose 10% year over ...

Beyfortus contains the active ingredient nirsevimab-alip,* and Synagis contains palivizumab. If you have other questions about how Beyfortus and Synagis compare, talk with your child’s doctor.

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

Find out whether you should get the RSV vaccine, known as Abrysvo, during pregnancy and when it's recommended.

Beyfortus won FDA approval in July as a passive immunization for RSV-related lower respiratory tract disease in newborns and infants born during or entering their first RSV season, plus young kids ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

The second trial included 1490 term and late-preterm infants, of which 994 received Beyfortus; 1.2% of infants on Beyfortus were infected with MA RSV LRTI vs 5.0% in the placebo group.